What are the average Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) levels in perimenopausal women?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 28, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Average LH and FSH Levels in Perimenopausal Women

Perimenopausal women typically have FSH levels ranging from 4-32 IU/L and LH levels ranging from 1.4-6.8 IU/L, with significant variability both between individuals and within the same woman over time. 1

Hormonal Characteristics of the Perimenopause

FSH Levels

  • FSH is consistently elevated throughout the perimenopausal transition, with mean levels significantly higher than in younger reproductive-aged women (4-32 IU/L versus 3-7 IU/L in controls) 1
  • FSH elevation occurs in both the follicular and luteal phases of the menstrual cycle during perimenopause 1
  • Short cycles in perimenopausal women show particularly high FSH concentrations throughout the cycle, while LH remains in the normal range 2
  • The average FSH level across all perimenopausal stages is approximately 60.46 ± 33.15 mIU/mL, though this includes women at various stages of the transition 3

LH Levels

  • LH secretion is overall greater in perimenopausal women compared to younger controls (1.4-6.8 IU/L versus 1.1-4.2 IU/L) 1
  • Isolated LH elevation into the postmenopausal range (without FSH elevation) occurs in approximately 58% of perimenopausal women during episodes lasting 2-8 weeks 4
  • During long anovulatory cycles in perimenopausal women, both LH and FSH concentrations may reach menopausal range levels 2

Important Patterns and Variability

Wide Hormonal Fluctuations

  • The hormone patterns in perimenopausal women vary dramatically both between individuals and from time to time in the same individual, ranging from ovulatory cycles with low premenopausal FSH levels to transient episodes indistinguishable from postmenopausal patterns 4
  • Approximately 45% of perimenopausal women experience episodes lasting 2-9 weeks where postmenopausal levels of FSH and LH occur in association with high estrogen levels—a pattern rarely seen at other times in reproductive life 4
  • Isolated FSH elevation (without LH elevation) into the postmenopausal range occurs in approximately 42% of perimenopausal women during episodes lasting 1-2 weeks 4

Comparison to Other Life Stages

  • Perimenopausal FSH levels are significantly lower than in postmenopausal women (4-32 IU/L versus 24-85 IU/L) and women with premature ovarian failure (36-82 IU/L) 1
  • Perimenopausal LH levels are similarly lower than postmenopausal levels (1.4-6.8 IU/L versus 4.3-14.8 IU/L) 1
  • Ovulatory cycles with normal gonadotropin levels can occur at all stages of perimenopause, even within 16 weeks of the final menstrual period 4

Clinical Implications and Pitfalls

Diagnostic Limitations

  • Serum FSH and estradiol levels alone are not accurate enough to definitively diagnose perimenopause, as single measurements cannot capture the dynamic hormonal fluctuations characteristic of this transition 3
  • Postmenopausal biochemical parameters (elevated FSH and LH) are no guarantee of the postmenopausal state, as ovulatory cycles can resume even after gonadotropins reach menopausal levels 4
  • Clinicians should diagnose perimenopause based on menstrual history and age rather than relying solely on laboratory testing 3

Associated Hormonal Changes

  • Perimenopausal women demonstrate hyperestrogenism with overall mean estrone conjugate excretion significantly greater than younger women (76.9 ng/mg Cr versus 40.7 ng/mg Cr), elevated in both follicular and luteal phases 1
  • Luteal phase progesterone excretion is diminished compared to younger women, reflecting declining ovarian function 1
  • These hormonal alterations—hypergonadotropism, hyperestrogenism, and decreased progesterone—may be responsible for the increased gynecological morbidity characteristic of the perimenopausal period 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.